Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas cortical GAD67 reduction and subsequent GABA level decrease are consistently observed in schizophrenia and depression, it remains unclear how these GABAergic abnormalities contribute to specific symptoms.
|
29362511 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We also found suggestive associations in women for GAD1, GRIA3, and BDNF with depression accompanied by fatigue, and for CRHR1 with depression accompanied by early morning awakenings.
|
19548263 |
2010 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two scoring methods were used to convert the scores on the PHQ-9, GAD-7 and K6 to the PROMIS depression and anxiety metrics.
|
29872956 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This hypothesis is supported by a higher rate of suicide among male Test cricketers when compared with the UK male general population.<sup>1</sup> METHODS: This study ascertained rates of anxiety and depression by screening professional cricket players using the Generalised Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-9).
|
28490460 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were a significant 58% increase of SCN GAD65/67-ir and a significant 169% increase of SCN GAD67-mRNA in the depression group.
|
28608287 |
2017 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The resulting groups were characterized with regard to Quality of Life (MacNew), anxiety and depression (GAD-7 and PHQ-9) and resilience (RS-13).
|
28006984 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The response rate, as measured by a 50% decrease in scores, for those with initial scores ≥10 was 58.6% for depression (PHQ-9) and 50% for anxiety (GAD-7).
|
28165775 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall findings suggest that the workbook format was no less effective or acceptable than the validated online format.Significant improvements (avg. improvement; Internet Group vs Workbook Group) in levels of disability (PDI: 16% vs 24%; RMDQ: 12% vs 15%), anxiety (GAD-7: 36% vs 26%), and depression (PHQ-9: 36% vs 36%) were observed in both groups immediately posttreatment.
|
28394850 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GAD67-mediated depression became stable after 14 weeks.
|
30788386 |
2019 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PWE from rural West China were evaluated for depression and anxiety with the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 (GAD-7; Chinese version).
|
30125939 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Primary outcomes included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.
|
28057609 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prevalence estimates for depressive disorder (CIDI), depressive symptoms (BDI ≥ 16), anxiety symptoms (GAD-7 ≥ 10) and PTSD (PCL-C DSM criteria) were 3.8, 5.9, 3.6, and 4.5% respectively for twins and 3.9, 9.8, 5.1 and 5.4% for singletons.
|
29343229 |
2018 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with PNES had higher self-reported anxiety and depression levels (GAD-7: p = 0.04, PHQ-9: p < 0.01; BDI-II: p < 0.01) but similar QOL to PWE (p = 0.78).
|
31759316 |
2020 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial.
|
28242498 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; <i>P</i>=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; <i>P</i>=0.91).
|
29025788 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mean post treatment PHQ-9 and GAD-7 scores remained above threshold for those receiving CBT_DA but not those receiving CBT-D.
|
30048513 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the third trimester, a second FOBS score, and saliva sample were collected, and the Personal Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) were administered to measure depression and anxiety respectively.
|
31306998 |
2019 |